Planned Semi-Elective Lung Tx Study
Launched by UNIVERSITY OF FLORIDA · Oct 20, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Planned Semi-Elective Lung Transplant Study is investigating how the timing of lung transplants affects the outcomes for patients receiving these life-saving organs. Specifically, the study looks at cases where donor lungs are available late at night or early in the morning and whether starting the transplant procedure in the morning, after preserving the lungs in a special refrigerator, can lead to better results compared to traditional transplant methods.
To participate in this study, individuals must be between the ages of 65 and 74 and be eligible for their first lung transplant, with consent from them or their caregiver. Unfortunately, those who have previously had a lung transplant or are receiving multiple organ transplants are not eligible. Participants can expect to have their surgery scheduled in the morning if donor lungs are available during the designated late-night hours, and their health outcomes will be closely monitored to see how this new approach works. This study aims to improve lung transplant procedures and outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary lung transplantation
- • Informed consent provided
- • Donor Inclusion: Age\<70
- Exclusion Criteria:
- • Re-transplantation
- • Multi-organ transplantation
- Donor exclusion criteria:
- • Age \>70y
- • Concerns with organ preservation technique
About University Of Florida
The University of Florida, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials. With a focus on enhancing patient outcomes and exploring new therapeutic avenues, the university leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct rigorous research across a variety of medical fields. Committed to ethical standards and patient safety, the University of Florida fosters collaboration among researchers, healthcare professionals, and community stakeholders to translate scientific discoveries into impactful clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gainesville, Florida, United States
Patients applied
Trial Officials
Mindaugas Rackauskas, MD, PhD
Principal Investigator
University of Florida
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials